Serenoa repens was not more effective than placebo for treatment of urinary symptoms consistent with BPH
BACKGROUND Benign prostatic hyperplasia ( BPH ) , a nonmalignant enlargement of the prostate , can lead to obstructive and irritative lower urinary tract symptoms ( LUTS ) .
The pharmacologic use of plants and herbs ( phytotherapy ) for the treatment of LUTS associated with BPH is common .
The extract of the berry of the American saw palmetto , or dwarf palm plant , Serenoa repens ( also known by its botanical name of Sabal serrulatum ) , is one of several phytotherapeutic agents available for the treatment of BPH .
OBJECTIVES This systematic review aim ed to assess the effects of Serenoa repens in the treatment of LUTS consistent with BPH .
Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH)
Because benign prostatic hyperplasia ( BPH ) is relatively common , it is important to discover safe and effective means to treat this often debilitating perturbation . Accordingly , we examined the effectiveness of a combination of natural products ( cernitin , saw palmetto , B-sitosterol , vitamin E ) in treating symptoms of BPH . We undertook a r and omized , placebo-controlled , double-blind study . Patients were enrolled from 3 urological practice s in the USA . 144 subjects were r and omized for study . 17 subjects eventually withdrew , leaving 70 patients in the test group and 57 in the placebo group to complete the study . Inclusion criteria consisted of a diagnosis of BPH , no evidence of cancer , and a maximal urinary flow rate between 5 and 15 ml/second . Patients received either placebo or the combined natural products for 3 months . Evaluations were performed via the American Urological Association ( AUA ) Symptom Index score , urinary flow rate , PSA measurement , and residual bladder volume . Nocturia showed a markedly significant decrease in severity in patients receiving the combined natural products compared to those taking placebo ( p < 0.001 ) . Daytime frequency was also lessened significantly ( p < 0.04 ) . When the average individual total AUA Symptom Index score in the test group was compared to that in the placebo group at the end of the study , the difference proved highly significant ( p < 0.014 ) . PSA measurements , maximal and average urinary flow rates , and residual volumes showed no statistically significant differences . When taken for 3 months , a combination of natural products ( cernitin , saw palmetto , B-sitosterol , vitamin E ) compared to placebo can significantly lessen nocturia and frequency and diminish overall symptomatology of BPH as indicated by an improvement in the total AUA Symptom Index score . The combination of natural products caused no significant adverse side effects
Serenoa repens was not more effective than placebo for treatment of urinary symptoms consistent with BPH
BACKGROUND Benign prostatic hyperplasia ( BPH ) , a nonmalignant enlargement of the prostate , can lead to obstructive and irritative lower urinary tract symptoms ( LUTS ) .
The pharmacologic use of plants and herbs ( phytotherapy ) for the treatment of LUTS associated with BPH is common .
The extract of the berry of the American saw palmetto , or dwarf palm plant , Serenoa repens ( also known by its botanical name of Sabal serrulatum ) , is one of several phytotherapeutic agents available for the treatment of BPH .
OBJECTIVES This systematic review aim ed to assess the effects of Serenoa repens in the treatment of LUTS consistent with BPH .